| Name | Title | Contact Details |
|---|
CSL Behring is a biopharmaceutical company, manufacturing plasma-derived and recombinant therapeutic products and providing them to people in more than 100 countries.
Bournewood Hospital is a full-service, independent psychiatric hospital licensed for 90 beds, which has been in continuous operation as a psychiatric hospital on twelve acres in South Brookline since 1895
Kirby Lester Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Lake Forest, IL. To find more information about Kirby Lester Inc., please visit www.kirbylester.com
Grapefruit offers Health & Wellness Solutions including telehealth, tele-psychiatry/therapy, and behavioral health services. Having worked with school districts across the country during the pandemic, Grapefruit understands the administrative burdens the schools faced during the pandemic. Grapefruit knows that a successful, comprehensive program should include access along the continuum of care — from health promotion and prevention, to treatment. With a comprehensive telemedicine program, schools have the ability to address both the physical and behavioral needs of each child. Guidance Counselors, school nurses and the school administration are not equipped or trained to handle the increased need for mental and behavioral health our youth is plagued with. Grapefruit recognizes the critical nature of providing these services to children and young adults, now more than ever.
Portola Pharmaceuticals is dedicated to developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. Our two lead assets are Bevyxxa® (betrixaban), and andexanet alfa. In addition, cerdulatinib is our investigational Syk/JAK inhibitor to treat hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.